secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolus, Inc. (EOLS)
CIK:        0001570562
Form:       8-K
Filed at:   2022-08-02T23:59:59+00:00
Accession:  0001570562-22-000116
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolus Q2 revenue $37.2M (+42% YoY); reaffirms FY upper-end guidance $143-150M
------------------------------------------------------------------------------

- Q2 net revenue $37.2M, up 42% YoY; gross margin 55.4% (adj. 57.4%); operating loss $21.3M.
- Reaffirms FY2022 revenue guidance upper end of $143-150M, expects ~50% YoY growth.
- Cash $84.5M; expects funding to cash-flow breakeven; Q4 gross margin step-up to 68-71% after royalty end.
- European Nuceiva launch on track for Q3 2022; Phase II 'extra strength' Jeuveau enrollment completed.
- Added 590 new customer accounts in Q2; total >8,100 purchasing customers; reorder rate >70%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1570562/000157056222000116/0001570562-22-000116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1570562/000157056222000116/eols-20220802.htm
  HTML page:      https://secwatch.observer/filing/0001570562-22-000116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer